Home » Newsletters » BioWorld

BioWorld

Oct. 7, 1992

View Archived Issues

BOEHRINGER BUYS 6.8% OF NEORX

RAC APPROVES GENE THERAPY TRIAL FOR LUNG CANCER

NEW ROLE FOR MACROPHAGES IN LDL

PROGENICS GETS $50,000 GRANT

$450,000 GRANT FOR PHARMOS

FDA CERTIFIES MULTIPLE PEPTIDE

INTERNATIONAL MUREX TO CONSOLIDATE

LIGAND FILES FOR 3 MILLION-SHARE IPO

SENATE EXPECTED TO PASS USER FEES

ADVANCED TISSUE GETS SBIR GRANT

ABI, PERKIN-ELMER IN $330M MERGER

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 9, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Omada, Caris arrivals continue med-tech IPO hot streak
BioWorld MedTech
Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...